Integer Holdings Corporation Completes Leadership Transition as Payman Khales Becomes President and CEO

Integer Holdings Corporation announces Payman Khales as new CEO, succeeding Joseph Dziedzic, who will remain as an advisor.

Quiver AI Summary

Integer Holdings Corporation announced the completion of a planned leadership transition, with Payman Khales becoming the new President and Chief Executive Officer, effective immediately. Khales succeeds Joseph Dziedzic, who is retiring after eight years in the role but will remain as an advisor until March 31, 2026. Khales joined Integer in 2018, where he led significant growth in the Cardio & Vascular business and most recently served as Chief Operating Officer, enhancing the company's global operations. He expressed enthusiasm for leading Integer, emphasizing innovation and collaboration to deliver impactful medical technologies to patients. Khales holds an Executive MBA from Indiana University and a Mechanical Engineering degree from École Polytechnique de Montréal.

Potential Positives

Payman Khales has assumed the role of President and CEO, signifying a planned leadership transition which can ensure continuity and fresh perspectives at the executive level.
Mr. Khales has a strong track record of doubling sales and driving above-market growth in his previous roles at Integer, suggesting potential for further business development under his leadership.
Joseph Dziedzic will remain as an advisor until March 31, 2026, which can facilitate a smoother transition and leverage his experience for ongoing strategic initiatives.
Integer Holdings Corporation is recognized as one of the largest CDMOs in the world, reinforcing its strong position in the market and commitment to enhancing patient lives through innovative medical technologies.

Potential Negatives

FAQ

Who is the new CEO of Integer Holdings Corporation?

Payman Khales has assumed the role of President and Chief Executive Officer of Integer Holdings Corporation.

What is the background of Payman Khales?

Mr. Khales joined Integer in 2018 and previously held leadership roles at CECO Environmental Corp. and Ingersoll Rand Company.

When did the leadership transition at Integer take place?

The planned leadership transition was completed on October 24, 2025.

What will Joseph Dziedzic’s role be after retiring?

Joseph Dziedzic will continue to serve as an advisor until March 31, 2026.

What are Integer's key markets?

Integer serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets globally.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ITGR Insider Trading Activity

$ITGR insiders have traded $ITGR stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $ITGR stock by insiders over the last 6 months:

JOSEPH W DZIEDZIC (President & CEO) has made 0 purchases and 3 sales selling 338,975 shares for an estimated $41,751,432.
DONALD J SPENCE sold 14,739 shares for an estimated $1,774,339
MARTIN C MAXWELL has made 0 purchases and 5 sales selling 8,720 shares for an estimated $1,051,278.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ITGR Hedge Fund Activity

We have seen 185 institutional investors add shares of $ITGR stock to their portfolio, and 159 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL RESEARCH GLOBAL INVESTORS removed 1,342,493 shares (-96.4%) from their portfolio in Q2 2025, for an estimated $165,086,364
ALLIANCEBERNSTEIN L.P. added 993,810 shares (+885.1%) to their portfolio in Q2 2025, for an estimated $122,208,815
FULLER & THALER ASSET MANAGEMENT, INC. removed 546,759 shares (-68.8%) from their portfolio in Q2 2025, for an estimated $67,234,954
CITADEL ADVISORS LLC added 408,980 shares (+1606.4%) to their portfolio in Q2 2025, for an estimated $50,292,270
JPMORGAN CHASE & CO added 295,364 shares (+295.6%) to their portfolio in Q2 2025, for an estimated $36,320,911
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. removed 282,485 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $34,737,180
DRIEHAUS CAPITAL MANAGEMENT LLC removed 264,356 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $32,507,857

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ITGR Analyst Ratings

Wall Street analysts have issued reports on $ITGR in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Keybanc issued a "Overweight" rating on 10/21/2025
Raymond James issued a "Outperform" rating on 07/25/2025
Wells Fargo issued a "Overweight" rating on 07/25/2025
Truist Securities issued a "Buy" rating on 07/25/2025
Citigroup issued a "Buy" rating on 05/22/2025

To track analyst ratings and price targets for $ITGR, check out Quiver Quantitative's $ITGR forecast page.

$ITGR Price Targets

Multiple analysts have issued price targets for $ITGR recently. We have seen 5 analysts offer price targets for $ITGR in the last 6 months, with a median target of $133.0.

Here are some recent targets:

Brett Fishbin from Keybanc set a target price of $133.0 on 10/21/2025
Richard Newitter from Truist Securities set a target price of $121.0 on 10/15/2025
Andrew Cooper from Raymond James set a target price of $143.0 on 07/25/2025
Nathan Treybeck from Wells Fargo set a target price of $132.0 on 07/25/2025
Joanne Wuensch from Citigroup set a target price of $140.0 on 05/22/2025

Full Release

~ Planned Leadership Transition Completed ~

PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company’s Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition.

Mr. Khales joined Integer in 2018 as President of the Cardio & Vascular business, where he led a successful market- and customer-focused strategy, doubling sales in seven years and driving above-market growth, while further improving service levels and profitability. Most recently, as Chief Operating Officer, he oversaw both of Integer’s business units and its global operations, further strengthening Integer’s reputation as a strategic partner to medical device companies and OEMs worldwide.

“It is a privilege to step into the role of CEO at Integer,” said Mr. Khales. “I am energized by the opportunities ahead as we continue to advance our strategy. Together with our talented associates, we will create value by innovating, collaborating with our customers, and delivering life-changing medical technologies to patients around the world. I am grateful to Joe for his mentorship and support, and I look forward to leading Integer.”

Prior to joining Integer, Mr. Khales held senior leadership roles at CECO Environmental Corp. and Ingersoll Rand Company. He holds an Executive MBA from Indiana University’s Kelley School of Business and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal.

About Integer ^®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company’s brands include Greatbatch Medical ^® and Lake Region Medical ^® . Additional information is available at www.integer.net .

Investor Relations:	Media Relations:
Kristen Stewart	Lauren Ban
[email protected]	[email protected]
551.337.3973	469.476.9615